NervGen Pharma (NASDAQ:NGEN) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of NervGen Pharma (NASDAQ:NGEN) from a sell rating to a strong sell rating in a research report sent to investors on Wednesday morning.

NGEN has been the topic of a number of other research reports. Weiss Ratings started coverage on shares of NervGen Pharma in a report on Friday, April 24th. They issued a “sell (d-)” rating on the stock. HC Wainwright raised shares of NervGen Pharma to a “strong-buy” rating in a report on Tuesday, April 28th. Zacks Research raised shares of NervGen Pharma to a “hold” rating in a report on Wednesday, April 29th. Finally, Stifel Nicolaus raised shares of NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

NervGen Pharma Trading Down 2.4%

NGEN opened at $3.64 on Wednesday. NervGen Pharma has a 52-week low of $1.50 and a 52-week high of $6.30.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.